Searched for
CIPLA HETERO
Hetero gets DGCI approval for generic version of tocilizumab for treatment of Covid-19"The Drug Controller General of India (DCGI) has issued for restricted use, Emergency Use Authorisation (EUA) for the generic version of To...- Supply delays, rise in Covid-19 cases lead to Remdesivir shortageIn India, companies such as Cipla, Dr Reddy’s, Hetero, Mylan, Zydus Cadila and Jubilant have the licence to manufacture the drug. Each of t...
- Supply delays, rise in Covid cases lead to Remdesivir shortageIn Maharashtra, which has the highest number of Covid-19 cases in the country, the state health minister said due to batch failures of cert...
- Cipla launches generic version of remdesivir at Rs 4,000 per vial"We are proud to commercially launch Cipremi today (on Wednesday); amongst the lowest priced globally, and aim to supply over 80,000 vials ...
- These are the companies manufacturing COVID-19 drug Remdesivir in India
- Gilead won't launch its Covid drug in JulyGilead has issued licences to nine generic drug companies to make and sell remdesivir. Six of the companies are Indian - Hetero, Cipla, Dr ...
- Pharma major Mylan gets go-ahead to make remdesivir for 'restricted emergency use'Written informed consent of each patient is required before the use of the drug while active post-marketing surveillance data and reporting...
- Hetero Healthcare set to supply its generic COVID-19 drug at Rs 5,400 per vial across IndiaThe company is set to deliver the first set of 20,000 vials in two equal lots of 10,000 each, one of which will be immediately supplied to ...
- Hetero, Cipla to supply generic Remdesivir to hospitals this weekThe recommended course for a Covid-19 patient under oxygen support is five vials. The approved therapy is for moderate to severe patients.
- Covid-19 treatment: Cipla, Hetero Lab get nod to manufacture and sell RemdesivirCipla, Hetero, and Jubilant Lifesciences have signed voluntary licensing agreements with Gilead.
- NPPA lens on five pharma companies for Hepatitis C drug overchargeNPPA has sent show-cause notices to these companies alleging overcharging for the combination drug used to treat the potentially fatal Hepa...
- Cipla should launch 10 odd products in the FY17: Umang Vohra, Global COO"Cipla FY16 guidance of 20-22 per cent revenue growth and 100 to 150 bps margin improvement for this year does not include InvaGen"
- Post Invagen sale, Hetero says to strengthen US operationsCipla said the group, through its subsidiary Camber Pharmaceuticals Inc., will continue to strengthen its operations in the US.
- Cipla set to buy American business of Hetero Drugs for $550 millionPeople close to the transaction said Cipla will buy Invagen and Camber, Hetero’s wholly owned subsidiary, for about $550 million.
- Hetero buy will boost Cipla's US ops in next 2-3 years; hold stock @ target of Rs 755: Praful Bohra, Religare"Cipla's portfolio is of a commodity generics type; so this will definitely place it in a strong position in terms of product pipeline in t...
- Hetero launches biosimilar Rituximab in IndiaHyderabad based Hetero pharma has launched biosimilar drug Rituximab under the brand name of MABALL, used in the treatment of blood cancer.
- Natco in talks with pharma retail chainsHyderabad-based drug company Natco Pharma, which launched its anti-HINI drug 'Natflu' in the national capital, said it is talking with vari...
- Natco in race for govt dealNatco is in race to bag a government contract for supply of 10 million Tamiflu, used to treat swine flu.
- Hetero bags deal for 10 m TamifluHetero Drugs has pipped Ranbaxy Laboratories, Cipla, Natco Pharma, Strides Arcolabs and Roche India to bag half the government order to sup...
- AIDS drug Tenofovir price set to crashBlockbuster AIDS drug Tenofovir is set to get cheaper after its inventor and US patent holder Gilead struck non-exclusive licensing deals w...
Load More
